Patients who receive iron by infusion rather than by tablet now sit at the centre of a safety review that could change prescribing across 27 health systems. The pharmacovigilance committee at the European Medicines Agency opened the review at its meeting from 31 August to 3 September, and it covers every injectable iron product on the European market.
The concern is hypophosphataemia, meaning abnormally low phosphate in the blood, and the bone disease that can follow when the deficit persists. Severe or prolonged phosphate depletion can soften bone, a condition clinicians call osteomalacia, and it produces pain and fractures that patients rarely connect to an infusion they received months earlier.
Regulators already know the signal. Ferric carboxymaltose carries the strongest evidence and drew earlier warnings and monitoring advice. The new review goes wider and takes in all injectable formulations, because the committee wants to establish whether the existing risk-minimisation measures actually work in clinical practice. Oral iron falls outside the scope, since tablets deliver far smaller doses over a far longer period.
The clinical stakes explain the caution. Iron infusions have moved from specialist use into routine care over the past fifteen years. Doctors prescribe them for heavy menstrual bleeding, inflammatory bowel disease, chronic kidney disease, heart failure and pre-surgical optimisation. Hospitals favour them because one visit replaces months of tablets that many patients abandon, and day units across Europe now run high volumes.
The committee will judge whether the risks alter the overall benefit-risk balance and whether marketing authorisations need changing. Its options run from strengthened product information and explicit phosphate monitoring advice through to restrictions on repeat dosing in defined patient groups. Nobody expects a withdrawal, and the therapeutic gap left by one would be substantial.
A second question sits underneath the first, and it concerns the system rather than the medicine. Brussels rebuilt European pharmacovigilance after the 2012 legislation precisely to catch this pattern, where a known risk keeps surfacing despite mitigation already in place. Clinicians will reasonably ask why warnings issued years ago did not settle the matter, and the answer will say something about how well label changes travel into prescribing habits.
Nothing changes for patients this week. Reviews of this kind run for months, the committee then sends a recommendation to the human medicines committee, and a Commission decision follows to make any outcome binding across the Union. Anyone due an infusion should keep the appointment and raise questions with the prescriber rather than act on the announcement alone.
Haematologists and nephrologists will watch the phosphate data closely, because the practical fix may prove simple. A baseline test, a follow-up test after repeat dosing and a clear threshold for intervention would cost little. Whether the committee asks for that, or for something firmer, becomes clear when it publishes its assessment.
